HK1043309A1 - 影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法 - Google Patents

影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法 Download PDF

Info

Publication number
HK1043309A1
HK1043309A1 HK02104818.0A HK02104818A HK1043309A1 HK 1043309 A1 HK1043309 A1 HK 1043309A1 HK 02104818 A HK02104818 A HK 02104818A HK 1043309 A1 HK1043309 A1 HK 1043309A1
Authority
HK
Hong Kong
Prior art keywords
cholesterol
density lipoprotein
low density
methods
compositions
Prior art date
Application number
HK02104818.0A
Other languages
English (en)
Chinese (zh)
Inventor
Jaye Michael
J. Lynch Kevin
V. Amin Dilip
Thi Doan Kim-Anh
Marchadier Dawn
Maugeais Cyrille
J. Rader Daniel
A. Krawiec John
J. South Victoria
Original Assignee
Aventis Pharmaceuticals Inc.
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Aventis Pharmaceuticals Inc., The Trustees Of The University Of Pennsylvania filed Critical Aventis Pharmaceuticals Inc.
Publication of HK1043309A1 publication Critical patent/HK1043309A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK02104818.0A 1999-03-26 2000-03-24 影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法 HK1043309A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US09/277,401 1999-03-26
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Publications (1)

Publication Number Publication Date
HK1043309A1 true HK1043309A1 (zh) 2002-09-13

Family

ID=23060703

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104818.0A HK1043309A1 (zh) 1999-03-26 2000-03-24 影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法

Country Status (13)

Country Link
EP (1) EP1171078A4 (enExample)
JP (1) JP2002540127A (enExample)
KR (2) KR100887164B1 (enExample)
AU (1) AU776684B2 (enExample)
BR (1) BR0009333A (enExample)
CA (1) CA2363486C (enExample)
HK (1) HK1043309A1 (enExample)
IL (2) IL145526A0 (enExample)
MX (1) MXPA01009727A (enExample)
NO (2) NO331779B1 (enExample)
NZ (2) NZ514350A (enExample)
WO (1) WO2000057837A2 (enExample)
ZA (1) ZA200107598B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
EP2370582B1 (en) 2008-12-04 2017-05-10 CuRNA, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CN102317458B (zh) 2008-12-04 2018-01-02 库尔纳公司 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
PT2396038E (pt) 2009-02-12 2016-02-19 Curna Inc Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
CA2755409C (en) 2009-03-16 2019-04-30 Joseph Collard Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
JP5904935B2 (ja) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
EP2427553A4 (en) 2009-05-06 2012-11-07 Opko Curna Llc TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT
ES2664590T3 (es) 2009-05-18 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación
CN102549158B (zh) 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CN102695797B (zh) 2009-06-16 2018-05-25 库尔纳公司 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
ES2629339T3 (es) 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
KR101807324B1 (ko) 2009-06-26 2017-12-08 큐알엔에이, 인크. 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
WO2011011700A2 (en) 2009-07-24 2011-01-27 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011019815A2 (en) 2009-08-11 2011-02-17 Curna, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8791087B2 (en) 2009-08-21 2014-07-29 Curna, Inc. Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
CN102791861B (zh) 2009-09-25 2018-08-07 库尔纳公司 通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病
KR101823702B1 (ko) 2009-12-16 2018-01-30 큐알엔에이, 인크. 막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
KR101793753B1 (ko) 2009-12-23 2017-11-03 큐알엔에이, 인크. 커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
ES2657452T3 (es) 2009-12-29 2018-03-05 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1
CN102770540B (zh) 2009-12-29 2017-06-23 库尔纳公司 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
RU2016115782A (ru) 2009-12-31 2018-11-28 Курна, Инк. Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
JP5976548B2 (ja) 2010-02-22 2016-08-23 カッパーアールエヌエー，インコーポレイテッド Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
TWI600759B (zh) 2010-04-02 2017-10-01 可娜公司 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病
US9044494B2 (en) 2010-04-09 2015-06-02 Curna, Inc. Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
US9089588B2 (en) 2010-05-03 2015-07-28 Curna, Inc. Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP2576784B1 (en) 2010-05-26 2017-11-15 CuRNA, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
EP3299464B1 (en) 2010-05-26 2019-10-02 CuRNA, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
JP6023705B2 (ja) 2010-06-23 2016-11-09 カッパーアールエヌエー，インコーポレイテッド ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
EP2643463B1 (en) 2010-11-23 2017-09-27 CuRNA, Inc. Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
EP2718439B1 (en) 2011-06-09 2017-08-09 CuRNA, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2753317B1 (en) 2011-09-06 2020-02-26 CuRNA, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
HK1210211A1 (en) 2012-03-15 2016-04-15 科纳公司 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102628060A (zh) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 一种低脂奶的生产方法
US9695462B2 (en) 2012-11-05 2017-07-04 Shionogi & Co., Ltd. Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity
MY166357A (en) * 2013-03-14 2018-06-25 Shionogi & Co Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
TWI688575B (zh) 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20240277861A1 (en) * 2021-07-26 2024-08-22 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507203A (ja) * 1992-12-04 1996-08-06 イノーバー ラボラトリーズ，インコーポレイテッド 調節可能な核酸治療およびそれらの使用方法
DE69732789T2 (de) * 1996-12-06 2005-08-11 Aventis Pharmaceuticals Inc. Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Also Published As

Publication number Publication date
AU776684B2 (en) 2004-09-16
MXPA01009727A (es) 2002-07-22
KR20050044812A (ko) 2005-05-12
IL145526A0 (en) 2002-06-30
KR20020029651A (ko) 2002-04-19
CA2363486C (en) 2012-12-18
EP1171078A2 (en) 2002-01-16
AU3918700A (en) 2000-10-16
NO20014657D0 (no) 2001-09-25
NO20100214L (no) 2001-11-21
IL145526A (en) 2010-11-30
NO331784B1 (no) 2012-03-26
NZ531180A (en) 2005-06-24
CA2363486A1 (en) 2000-10-05
WO2000057837A2 (en) 2000-10-05
WO2000057837A8 (en) 2001-09-27
NO20014657L (no) 2001-11-21
BR0009333A (pt) 2002-01-08
EP1171078A4 (en) 2002-11-06
JP2002540127A (ja) 2002-11-26
WO2000057837A9 (en) 2001-10-18
ZA200107598B (en) 2003-05-28
NZ514350A (en) 2004-12-24
WO2000057837A3 (en) 2001-01-25
KR100887164B1 (ko) 2009-03-10
NO331779B1 (no) 2012-03-26

Similar Documents

Publication Publication Date Title
HK1043309A1 (zh) 影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
MX9702204A (es) Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
AU2001277957A1 (en) Stabilization of enzymes
WO2007053619A3 (en) A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
DK0738512T3 (da) Fremgangsmåde til forebyggelse af et andet hjerteanfald ved anvendelse af en HMG coenzsym A reduktasehæmmer
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
WO2003072714A3 (en) Follistatin domain containing proteins
WO2000061771A3 (en) Transgenic plants containing altered levels of sterol compounds and tocopherols
AU5173200A (en) Proximal femoral replacement implant and method of implanting the same
IL159368A0 (en) Method of modifying enzyme and oxidoreductase variant
AU2002317501A1 (en) Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient
WO2003061718A3 (en) Medical articles having enzymatic surfaces for localized therapy
GB9509321D0 (en) Methods of and substances for inhibiting oxidative enzymes
WO2005096704A3 (en) Cholesterol lowering composition
AU6028898A (en) Methods for cultivating cells and propagating viruses
AU2003207426A1 (en) Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
AU2002359403A1 (en) METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
AU2001243614A1 (en) Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
AU2002214644A1 (en) Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype
AU6833398A (en) Process for the inactivation of genes which code for enzymes for the catabolism of phenyl acetate, plasmids involved in such process and strains transformed t herewith
WO2002091926A3 (en) Inhibitors of dna methyltransferase isoforms